News
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results